微波消融序贯^131I-chTNT放射免疫法治疗肺癌的疗效及其对患者生存质量的影响

目的 探讨微波消融序贯^131I-肿瘤细胞核人鼠嵌合单克隆抗体（^131I-chTNT）放射免疫法治疗非小细胞肺癌的疗效及其对患者生存质量的影响.方法 将61例非小细胞肺癌患者随机分为两组,A组（32例）为外科手术治疗后放化疗,B组（29例）为微波消融联合^131I-chTNT放射免疫治疗后化疗.对两组患者进行临床疗效比较和生存质量评定.结果 治疗后6个月,A组局部病灶控制率为84.4％,B组为89.7％,两组相比,P＜0.05;两组不良反应发生率相近（P＞0.05）.治疗后6个月,两组患者生存质量评分均优于治疗前,其中B组的认知、情绪、社会功能量表及疼痛、呼吸困难症状量表评分结果与A组相比,P均＜0.05.结论 微波消融序贯^131I-chTNT放射免疫法治疗肺癌安全、有效,能明显提高肺癌患者生存质量.

Efficacy of microwave ablation combined with ^131I-chTNT radioimmunotherapy in treatment of lung cancer and its effect on life quality of patients

Objective To investigate the efficacy of sequential iodine-131-labeled tumor cell nucleus chimeric monoclonal antibody （^131I-chTNT） radioimmunotherapy combined with microwave ablation in treatment of non-small-cell lung cancer （NSCLC） and its effect on quality of life in patients.Methods A total of 61 cases of patients with NSCLC were randomly divided into two groups：group A （32 cases） undergoing chemotherapy after surgical treatment,and group B （29 cases） receiving chemotherapy after microwave ablation combined with ^131I-chTNT radioimmunotherapy.The clinical efficacy of two groups was compared,and the evaluation of quality of life was conducted.Results Six months after treatment,the local control rate of group A was 84.4%,and 89.7% in group B （P 〈 0.05）,but the adverse reactions in two groups was not statistically significant （P 〉0.05）.Quality of life scores after treatment were superior to those before treatment in group A and B,and significant differences were found in cognitive,emotional,social function scale,pain and dyspnea symptom scale scores between the two groups （all P 〈 0.05）.Conclusion ^131I-chTNT radioimmunotherapy combined with microwave ablation in treating NSCLC is safe and effective,which can significantly improve the quality of life in patients.